SYHA1815 / CSPC Pharma - LARVOL DELTA

A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2; N=97; Recruiting; Sponsor: Shanghai Runshi Pharmaceutical Technology Co., Ltd

Clinical • New P1/2 trial • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • CEACAM5 • FGF23 • FGFR • KDR • PD-L1

The novel RET inhibitor SYHA1815 inhibits RET-driven cancers and overcomes gatekeeper mutations by inducing G1 cell cycle arrest through c-Myc downregulation. (PubMed, Mol Cancer Ther) - "Notably, SYHA1815 exhibited approximately 20-fold selectivity for RET over KDR, almost equivalent to that of the launched selective inhibitor pralsetinib...Moreover, consistent with the marked in vivo efficacy of RET inhibition, the intratumoral c-Myc level was significantly decreased. In summary, SYHA1815 is a promising RETi for RET-aberrant cancer treatment that is currently in a phase I trial."

Journal • CNS Disorders • Oncology • Psychiatry • BRD4 • KDR • MYC • RET